Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide

Journal of Clinical Pharmacology

Volumn 50, Issue 5, 2010, Pages 554-565

  Brown, Karen S ^a   Armstrong, Ingrid C ^a   Wang, Antonia ^a   Walker, Joseph R ^a   Noveck, Robert J ^b   Swearingen, Dennis ^c   Allison, Mark ^c   Kissling, James C ^a   Kisicki, James ^a   Salazar, Daniel E ^a  

^a DAIICHI SANKYO INC   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MDS Inc   (Canada)

Author keywords

BA sequestrants glyburide; Colesevelam; Drug drug interactions; Ethinyl estradiol; Levothyroxine; Norethindrone; Pioglitazone; Repaglinide

Indexed keywords

BILE ACID SEQUESTRANT; COLESEVELAM; ESTRADIOL; GLIBENCLAMIDE; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; NORETHISTERONE; NORTREL; PIOGLITAZONE; REPAGLINIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BINDING COMPETITION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LEAST-SQUARES ANALYSIS; MALE; THYROXINE; TIME FACTORS;

EID: 77951193791     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009349378     Document Type: Article

References (37)

1. Lloyd-Jones DM, Larson MG, Beiser A., Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999 ; 353: 89-92. (Pubitemid 29088076)
2. Pekkanen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990 ; 322: 1700-1707. (Pubitemid 20231527)
3. Wilson PW, DAgostino RB, Levy D., Belanger AM, Silbershatz H., Kannel WB Prediction of coronary heart disease using risk factor categories. Circulation. 1998 ; 97: 1837-1847.
4. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2002 ; 287: 356-359.
5. Grundy SM, Ahrens EH Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 1971 ; 78: 94-121.
6. Shepherd J., Packard CJ, Bicker S., Lawrie TD, Morgan HG Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980 ; 302: 1219-1222.
7. Jacobson TA, Armani A., McKenney JM, Guyton JR Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol. 2007 ; 99: S47 - S55.
8. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results: I. Reduction in the incidence of coronary heart disease. JAMA. 1984 ; 251: 351-364.
9. Braunlin W., Zhorov E., Smisek D., et al. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints. 2000 ; 41: 708-709.
10. Davidson MH, Dillon MA, Gordon B., et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999 ; 159: 1893-1900.
11. Davidson MH, Toth P., Weiss S., et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001 ; 24: 467-474.
12. Hunninghake D., Insull W. Jr, Toth P., Davidson D., Donovan JM, Burke SK Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 ; 158: 407-416.
13. Knapp HH, Schrott H., Ma P., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 ; 110: 352-360. (Pubitemid 32248724)
14. Bays H., Rhyne J., Abby S., Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006 ; 22: 2191-2200.
15. Staels B., Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs. 2007 ; 67: 1383-1392.
16. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007 ; 29: 74-83.
17. WelChol [package insert]. Parsippany, NJ: Daiichi Sankyo ; 2008.
18. Bays HE, Dujovne CA Drug interactions of lipid-altering drugs. Drug Saf. 1998 ; 19: 355-371.
19. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens. 1993 ; 6: 375S - 382S.
20. Hunninghake DB, Hibbard DM Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide. Clin Pharmacol Ther. 1986 ; 39: 329-334.
21. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother. 2002 ; 36: 392-397.
22. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet. 2004 ; 43: 943-950. (Pubitemid 39447035)
23. Donovan JM, Stypinski D., Stiles MR, Olson TA, Burke SK Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther. 2000 ; 14: 681-690. (Pubitemid 32217192)
24. Walker JR, Brown KS, Rohatagi S., Xu C., Salazar DE, Mager DE Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (WelChol®). J Clin Pharm. In press.
25. Abbott Laboratories. LT4 Bioequivalence Briefing Document Appendix A, Abbott Laboratories Study M02417 Synopsis and Discussion, Advisory Committee for Pharmaceutical Science Held March 12-13, 2003. Chicago: Abbott Laboratories ; 2003.
26. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Guidance for Industry: Levothyroxine Sodium Tablets-In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing. Rockville, MD: FDA ; 2000.
27. Brown DD, Schmid J., Long RA, Hull JH A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J Clin Pharmacol. 1985 ; 25: 360-364. (Pubitemid 15007263)
28. Jahnchen E., Meinertz T., Gilfrich HJ, Kersting F., Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol. 1978 ; 5: 437-440. (Pubitemid 8325688)
29. Kivisto KT, Neuvonen PJ The effect of cholestyramine and activated charcoal on glipizide absorption. Br J Clin Pharmacol. 1990 ; 30: 733-736. (Pubitemid 20377603)
30. Hunninghake DB, King S., LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int J Clin Pharmacol Ther Toxicol. 1982 ; 20: 151-154.
31. Hibbard DM, Peters JR, Hunninghake DB Effects of cholestyramine and colestipol on the plasma concentrations of propranolol. Br J Clin Pharmacol. 1984 ; 18: 337-342. (Pubitemid 14033818)
32. Neuvonen PJ, Kivisto K., Hirvisalo EL Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol. 1988 ; 25: 229-233.
33. Kosoglou T., Statkevich P., Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005 ; 44: 467-494. (Pubitemid 40733733)
34. Johansson C., Adamsson U., Stierner U., Lindsten T. Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract. Acta Med Scand. 1978 ; 204: 509-512. (Pubitemid 9099752)
35. al-Balla SR, el-Sayed YM, al-Meshal MA, Gouda MW The effects of cholestyramine and colestipol on the absorption of diclofenac in man. Int J Clin Pharmacol Ther. 1994 ; 32: 441-445.
36. Malloy MJ, Ravis WR, Pennell AT, Hagan DR, Betagari S., Doshi DH Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics. Int J Clin Pharmacol Ther. 1994 ; 32: 286-289.
37. Malloy MJ, Ravis WR, Pennell AT, Diskin CJ Effect of cholestyramine resin on single dose valproate pharmacokinetics. Int J Clin Pharmacol Ther. 1996 ; 34: 208-211.